Zymeworks Inc. announced the voluntary discontinuation of clinical development of ZW171, a T cell engager targeting specific cancers.
The decision was based on completion of planned cohorts of the Phase 1 trial in patients with ovarian cancer and non-small cell lung cancer.
Further dose evaluation in the trial was deemed unlikely to support the desired benefit-risk profile.
Discontinuation Decision
Based on completion of planned trial cohorts and unfavorable benefit-risk profile assessment.
On-Target Toxicity
Dose-limiting toxicities related to mesothelin-targeted off-tumor effects were observed.
Future Product Pipeline
Focused on advancing ZW191 Phase 1 trial, initiating Phase 1 study for ZW251, and preparing for ZW209 IND filing in 2026.
- The discontinuation of ZW171 highlights the challenges in clinical development, emphasizing the importance of thorough risk-benefit assessments.
- Zymeworks' commitment to patient safety and resource allocation optimization is evident in the decision-making process.
While the discontinuation of ZW171 is a setback, Zymeworks remains dedicated to advancing its broader pipeline to deliver innovative therapies for difficult-to-treat conditions.